Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2023-11-08 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT 9M 2023' and covers the period from January to September 2023. It contains detailed financial tables (Key Ratios Group), a CEO statement, and comprehensive business updates, which confirms it is a substantive financial report for a period shorter than a full fiscal year, rather than just an announcement or a summary. 9M 2023
2023-11-08 English
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled "NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB". It details the date, time, and location for the meeting, outlines the procedures for shareholder participation (registration, proxies), and presents a proposed agenda with specific resolutions (e.g., Item 6 regarding an employee option program and warrant issue). This content is characteristic of materials distributed to shareholders in advance of a general meeting to inform them and solicit their votes, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI). While it relates to an 'Extraordinary General Meeting' (EGM), the primary function of this notice is solicitation/information, not the final voting results (DVA) or the general AGM presentation materials (AGM-R).
2023-10-19 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I ASCELIA PHARMA AB
AGM Information Classification · 99% confidence The document is titled "KALLELSE TILL EXTRA BOLAGSSTÄMMA I ASCELIA PHARMA AB" (Notice of Extraordinary General Meeting in Ascelia Pharma AB). It details the date, time, location, registration requirements, agenda items, and proposed resolutions for an upcoming shareholder meeting. The key proposals involve establishing a new employee stock option program and issuing corresponding warrants to facilitate this. A notice calling for a general meeting, especially one detailing proposals for shareholder votes, directly corresponds to the definition of materials shared for a General Meeting. Since it is a formal notice calling for the meeting and outlining the voting items, the most appropriate classification is AGM-R (AGM Information), as an Extraordinary General Meeting (EGM) falls under the scope of general meetings, even though the specific content relates to capital structure changes (CAP) or remuneration (DEF 14A). However, the primary function of this document is the 'Notice' of the meeting itself.
2023-10-19 Swedish
Ascelia Pharma significantly reduces organization to reach SPARKLE headline results
Board/Management Information Classification · 99% confidence The document announces a significant organizational reduction, including the departure of the CFO, to focus resources on completing the re-evaluation of SPARKLE images and reaching headline results with existing funding. It mentions future updates on timelines and financial implications. Crucially, the document ends with an 'Attachments' section linking to the full announcement PDF. Since the text itself is an announcement about internal restructuring and future plans, and it is relatively short (under 5,000 characters) and points to an attached document for the full details, it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that this is a specific corporate action announcement (restructuring/personnel change) rather than a standard financial report, and it is presented as a release pointing to the full details, RPA is the most appropriate classification if the content is primarily the announcement itself, or RNS if it's a general regulatory disclosure. Since it details management changes (CFO leaving) and operational strategy shifts, and it's a formal release, I will check the definitions. It is not a DEF 14A (Remuneration), nor MANG (Board/Management Change announcement, though it involves management departure, it's focused on cost-cutting). Because it is a formal release announcing operational/personnel changes and directs the reader to the full document via an attachment link, RPA (Report Publication Announcement) is the best fit, as it announces the publication of this specific news item.
2023-08-31 English
Ascelia Pharma gör omfattande neddragning av organisationen för att nå headline-resultat med SPARKLE
Board/Management Information Classification · 95% confidence The document announces a significant downsizing of the organization (layoffs, CFO departure) by Ascelia Pharma to focus resources on achieving headline results from the SPARKLE study with existing funding. This type of announcement, detailing internal restructuring, management changes (CFO leaving), and operational focus shifts, strongly aligns with the definition of Board/Management Information (MANG). While it mentions financial consequences, the primary focus is organizational change and executive departure, not a formal earnings release (ER) or a comprehensive interim report (IR). The document is short and appears to be a press release announcing the action, rather than the full report itself, but the content is specifically about management/personnel changes.
2023-08-31 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALVÅRSRAPPORT 2023' (Half-Year Report 2023) covering the period January to June 2023. It contains comprehensive financial data, including income statements, cash flow, and balance sheet information, as well as detailed management commentary on business operations, clinical trial status (SPARKLE study), and future outlook. It is a formal interim financial report, not an announcement or a summary. H1 2023
2023-08-18 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.